Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction
Summary
Leading medical experts have described the recent trial data for the Moderna and Merck cancer vaccine as a significant clinical breakthrough for surgical melanoma patients. Despite this positive assessment from specialists, financial markets responded with a notably different reaction to the findings.
Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.